Activation of G protein-coupled receptors by ketone bodies: Clinical implication of the ketogenic diet in metabolic disorders

Valentina Spigoni¹, Gloria Cinquegrani¹, Nicolas Thomas Iannozzi¹, Giulia Frigeri², Giulia Maggiolo², Marta Maggi², Vanessa Parello¹ and Alessandra Dei Cas¹,²*

¹Endocrinology and Metabolic Diseases, Department of Medicine and Surgery, University of Parma, Parma, Italy, ²Division of Nutritional and Metabolic Sciences, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy

Ketogenesis takes place in hepatocyte mitochondria where acetyl-CoA derived from fatty acid catabolism is converted to ketone bodies (KB), namely β-hydroxybutyrate (β-OHB), acetoacetate and acetone. KB represent important alternative energy sources under metabolic stress conditions. Ketogenic diets (KDs) are low-carbohydrate, fat-rich eating strategies which have been widely proposed as valid nutritional interventions in several metabolic disorders due to its substantial efficacy in weight loss achievement. Carbohydrate restriction during KD forces the use of FFA, which are subsequently transformed into KB in hepatocytes to provide energy, leading to a significant increase in ketone levels known as “nutritional ketosis”. The recent discovery of KB as ligands of G protein-coupled receptors (GPCR) – cellular transducers implicated in a wide range of body functions – has aroused a great interest in understanding whether some of the clinical effects associated to KD consumption might be mediated by the ketone/GPCR axis. Specifically, anti-inflammatory effects associated to KD regimen can be ascribed to the actions of acetoacetate via GPR43 and of β-OHB via GPR109A on lipolysis. Thus, this review will focus on the effects of KD-induced nutritional ketosis potentially mediated by specific GPCRs in metabolic and endocrinological disorders. To discriminate the effects of ketone bodies per se, independently of weight loss, only studies comparing ketogenic vs isocaloric non-ketogenic diets will be considered as well as short-term tolerability and safety of KDs.

KEYWORDS
ketogenic diet, ketone bodies, GPCR (G protein coupled receptors), metabolic disorder, very low carbohydrate ketogenic diet
Introduction

Metabolism of ketone bodies

Ketone bodies (KB) - β-hydroxybutyrate (β-OHB), acetoacetate and the less abundant acetone - are produced by ketogenesis in the hepatocyte mitochondria and converted into energy in the mitochondria of several extrahepatic organs (i.e., brain, heart, kidney cortex and skeletal muscle) by ketolysis (Figure 1) (1).

Briefly, in the ketogenesis process, free fatty acids (FFA) mobilised from the adipose tissue are transported into the liver mitochondria by carnitine palmitoyltransferase (CPT1) and undergo β-oxidation resulting into two acetyl-CoA molecules subsequently condensed to acetoacetyl-CoA by acetyl coenzyme A acetyltransferase (ACAT1) (2). The condensation of acetoacetyl-CoA with a third molecule of acetyl-CoA, by β-hydroxy-β-methylglutaryl-CoA (HMG-CoA) synthase, leads to the formation of HMG-CoA, an intermediate in the mevalonate and ketogenesis pathways and a precursor of cholesterol biosynthesis (3). The HMG-CoA lyase converts the HMG-CoA to the β-keto acid acetoacetate, which, in turn, can be converted to acetone and CO₂ by non-enzymatic decarboxylation or to β-OHB by β-OHB-dehydrogenase. The liver releases β-OHB, which, in a process named ketolysis, is re-converted to acetoacetate and subsequently to acetyl-CoA by the succinyl-CoA-3-ketoacid-CoA transferase (SCOT), which is expressed in all mammalian cells with mitochondria, with the exception of hepatocytes (2) (Figure 1).

Acetyl-CoA enters the Krebs cycle for ATP production through oxidative phosphorylation.

KB utilization as metabolic substrate is energetically more efficient in terms of ATP synthesis per molecule of oxygen invested than glucose or FFA and allows the transfer of lipid-derived energy from liver to extrahepatic organs as an alternative fuel source (4). Alternatively, acetyl-CoA deviates from the Krebs cycle to lipid synthesis. Acetone does not convert backwards to acetyl-CoA and it is excreted through urine or exhaled (5).

Conditions associated to physiological ketosis

Several conditions are associated to physiological plasma ketosis. KB plasma levels are normally < 0.5mM, but during fasting, a decrease in insulin/glucagon ratio is paralleled by a concomitant increase in plasma FFA and KB, which, in the presence of a prolonged starvation, may excessively increase up to 5-fold (1.3 mM) and 20-fold (7-10 mM), respectively (6–8). Prolonged exercise may also induce a physiological increase in plasma KB up to 1-2 mM (1). Other biological conditions, such as pregnancy or the neonatal period, are associated to a mild increase in ketosis (1).
The nutritional ketosis following a ketogenic diet (KD) regimen also represents a physiological mechanism, in which KB concentrations are < 3.0 mM and blood pH remains within the normal range (1, 9). Conversely, diabetic ketoacidosis, a severe acute complication of diabetes, is a pathological condition in which KB reach extremely high plasma concentrations (≥ 3.0 mM) with a concomitant blood pH fall below the normal range (11). In diabetic conditions, insulin deficiency prompts the body to metabolize triglycerides and amino acids, instead of glucose, for energy. Serum levels of glycerol and FFA consequently rise due to exacerbated lipolysis (1). Moreover, glycerol provides the substrates for hepatic gluconeogenesis, which is further stimulated by the excess glucagon that accompanies insulin deficiency (1). In non-diabetic individuals, ketoacidosis is prevented as the preserved insulin secretion reduces the release of FFA from the adipose tissue, leading to a decreased ketogenesis in hepatocytes, accompanied by urinary KB excretion (9).

Thus, KB can be either a necessary nutrient or the reflection of a pathological status depending on their plasmatic concentrations.

**Definition and types of ketogenic diets**

KDs were first used since the 1920s to treat refractory epilepsy in children (12) and increasing evidence shows encouraging results in pathological conditions such as Alzheimer disease (13), cancer (14), and metabolic diseases (15). KDs are defined as low-carbohydrate (usually to < 50 g/day) and adequate protein intakes to induce ketosis without restricting fat intake (16). Similar to fasting conditions, during a carbohydrate-restricted diet, the body undergoes metabolic changes to provide an energy source relying on gluconeogenesis and ketogenesis. Following depletion of glycogen stores, the body is forced to use FFA, which are subsequently transformed into KB in hepatocytes, to provide energy (1). KB become the primary energy source by cells with mitochondria and, most importantly, by the brain. This significant rise in KB in course of KD it is known as "nutritional ketosis" (17), a condition in which plasma KB concentration physiologically increases (at least > 0.5 mM (18)), resulting in a rather safe nutritional approach (19).

Different variants of the KD have been defined in the last few years, although a commonly accepted classification is still lacking.

Types of KDs includes: the classic long-chain triglycerides (LCT) KD, which is the most used KD, and it contains four times as many grams of fat for every 1 g of protein and carbohydrates (4:1 ratio) (20, 21). The medium-chain triglyceride (MCT, C6–C12) KD is more ketogenic than (LCT KD); MCTs are readily absorbed into the portal vein -as they do not require micelle formation with bile acids- and are directly transformed into KB. The MCT KD allows the intake of a higher ratio of carbohydrates and protein compared to the high-fat KD with consequent increase in adherence and prevention of muscle catabolism (22). Differently from high fat KD, the MCT KD is built only on the percentage of calorie from MCT oil (23). MCT KD is commonly used for the treatment of refractory childhood epilepsy (24, 25) and other neurological disorders such as cognitive dysfunction in Alzheimer’s disease and mild cognitive impairment (26).

The very low carbohydrate ketogenic diet (VLCKD) represents the most widespread KD type and is traditionally characterized by carbohydrate limitation (<50 g per day) with unrestricted fat consumption and a moderate increase in protein intake (0.8-1.2 g per day) (27). The total amount of calories to be provided for a single individual is based on anthropometric measurements, dietary intake and physical activity (28).

The very low calorie KDs have an extremely low caloric intake (400–800 kcal/day) and contain an amount of protein of 1.2–1.4 g/kg of ideal body weight, a very limited carbohydrate content (< 30–50 g/day, < 5–10%) and a determined amount of fats (~20 g/day) (29).

Beyond calorie restriction, the increase in KB levels is associated with a specific anorexic effect, by preventing the increase in ghrelin secretion in response to weight loss, decreasing hunger (30). However, the exact threshold of ketosis needed to induce appetite suppression, as well as the exact mechanisms mediating such an effect, have yet to be elucidated (31). The suppression/blunting of hunger sensation and consequent reduction in caloric intake has a fundamental role in diet compliance and short-term weigh loss outcomes (32–34).

Generally, KDs are recommended for a limited time and the shift to a standard diet should be gradual and supervised (35). KDs may be fraught with side effects which usually disappear within a few days to a few weeks like nausea, vomiting, headache, tiredness, insomnia and exercise intolerance. Long-term adverse effects may include hepatic steatosis, hypoproteinemina and kidney stones (35). The main contraindications to implement a KD are pancreatitis, liver failure, primary carnitine deficiency, carnitine palmitoyltransferase deficiency, carnitine translocase deficiency, porphyrias, or pyruvate kinase deficiency (36).

It has recently emerged that KDs may hold additional beneficial effects on metabolism and cardiovascular risk reduction, which may be partially independent of weight loss. The increase in KB following a keto diet regimen would potentially produce tissue specific effects by the activation of cell membrane G protein-coupled receptors (GPCRs) which have been recently discovered to be engaged by β-OHB and acetocacetate.
G protein-coupled receptors (GPCRs)

GPCRs - which represent the largest protein family in the human proteome - are signal transducers located in the plasma membrane of eukaryotic cells. GPCRs share a common structure consisting of seven 25-amino acid α-helical segments crossing through the plasma membrane, with the amino-terminus and carboxy-terminus outside the cell and in the cytoplasm, respectively (37). The variety of ligands capable of binding to GPCRs is notable, ranging from a single photon to large proteins and including ions, odorants, nucleotides, peptides, amines, lipids and metabolic intermediates. Following ligand engagement, GPCRs interact with G proteins in the plasma membrane leading to the production of cAMP and of other second messengers. A subsequent cascade of phosphorylation, involving extracellular regulated protein kinases 1/2 (ERK1/2), transduces cellular responses by modulating cell metabolism and function (38).

Over time, the number of GPCRs discovered has increased as well as that of their binding energy substrates such as fatty acids and sucrose, and key metabolic intermediates including acetate and lactate (39–41). The recent discovery of KB as GPCR ligands has aroused a great interest in understanding whether some of the clinical effects associated to KDs might be mediated by ketone/GPCR axis; however, data are scarce in the literature.

Thus, this review will focus on the effects of KD-induced nutritional ketosis potentially mediated by specific GPCRs in metabolic and endocrinological disorders.

β-hydroxybutyrate reduces atherosclerosis and inflammation by engaging GPR109A

β-OHB is the most represented KB in humans and its concentrations typically reach ~0.2–0.4 mM after an overnight fast, ~1–2 mM following 2–3 days of fasting, and plateaus at ~6–8 mM upon prolonged starvation (1, 42–44).

Most of β-OHB actions seem to be mediated by the activation of a specific GPCR, namely GPR109A, also known as Hydroxy carboxylic Acid Receptor 2 (HCAR2). GPR109A is classically recognized as the receptor for butyrate and nicotinic acid and is abundantly expressed in adipocytes, macrophages, and neutrophils (45). The plasma concentrations of β-OHB able to engage GPR109A (EC50 = 0.77 ± 0.06 mM) (46) are those achievable after ~2–3 days of starvation (1), or following a ketogenic diet regimen (47–49).

The binding of β-OHB to GPR109A is implicated in the reduction of both lipid metabolism and inflammation (Table 1). In adipocytes, GPR109A activation results in G50/protein-mediated inhibition of adenylyl cyclase, leading to a mitigated cAMP response with a consequent reduction in hormone sensitive lipase activity, resulting in lipolysis inhibition (57). The consequent reduced FFA release and hepatic delivery limit substrate availability for hepatic triglyceride and has been proposed as a negative feedback mechanism in KB synthesis (46, 58). Accordingly, a calorie-restricted diet or β-OHB administration resulted in the suppression of hepatic lipid accumulation through GPR109A/AMP-activated protein kinase (AMPK) pathway in aged rats (51). If the results on lipolysis inhibition are robust, less consistent are the findings on the resulting modifications in plasma lipoprotein profile (59).

In addition to the effects on lipolysis inhibition, emerging evidence points to GPR109A as the molecular transducer of β-OHB-mediated effects also on the mitigation of the inflammatory burden, through the reduction in NLR family pyrin domain containing 3 (NLRP3) inflammasome activity (50). Briefly, the inflammasome is a multiprotein intracellular complex which can be activated by diverse signals such as endoplasmic reticulum (ER) stress, reactive oxygen species (ROS), and excessive Ca2+ leading to caspase 1 activation which in turn activates proinflammatory interleukin (IL)-1β and IL-18. Specifically, in macrophages, inflammasome activation triggers pro-atherogenic M1 polarization -in contrast to anti-inflammatory M2- contributing to the pro-inflammatory e pro-atherogenic environment (60).

A recent work demonstrated that the exogenous administration of 200 mg/kg/day of β-OHB resulted in a strong fat reduction in apoE−/− atherosclerotic mice even in the presence of a high-fat diet. β-OHB decreased pro-inflammatory M1 polarization and cholesterol accumulation in bone marrow-derived macrophages (BMDMs) (50). These protective effects were no longer evident in GPR109A−/− and NLRP3−/− BMDMs, indicating that β-OHB attenuates atherosclerosis via GPR109A-NLRP3 dependent pathway. Mechanistically, β-OHB - via GPR109A - promoted the influx of Ca2+ by reducing Ca2+ release from ER thereby maintaining Ca2+ storage and inhibiting its depletion induced by NLRP3 inflammasome activation. Overall, this study suggests that the treatment with β-OHB significantly blunts systemic inflammation and atherosclerosis mostly through GPR109A-expressing macrophages (50).

Most of the knowledge concerning the anti-inflammatory action of β-OHB mediated by GPR109A comes primarily from studies conducted in neurodegenerative diseases. Nicotinic acid, a GPR109A agonist, induced a neuroprotective phenotype of monocytes/macrophages in a mouse model of stroke resulting in the reduction of ischemic brain damage (45). GPR109A activation in macrophages led to Prostaglandin D2 (PGD2) production by Cyclooxygenase (COX)-1 and PGD2 synthase, underscoring the key role of PGD2 in the regulation of inflammation and innate immune response (61).

Another study demonstrated that β-OHB, inhibited pro-inflammatory enzyme and cytokine [tumor necrosis factor
(TNF-α, IL-1β, and IL-6) production in microglia via GPR109A, through the reduction of nuclear factor-kB (NF-kB) activation (52). This anti-inflammatory action of β-OHB has been recently proposed as a tool to prevent (or slow down) also the progression of Parkinson’s disease.

GPR109A-mediated anti-inflammatory action of β-OHB was shown to be also protective in alcohol hepatitis, characterized by liver inflammation which may progress into systemic inflammatory response and high neutrophil infiltration in the liver (62). The β-OHB intake in mice has an anti-inflammatory and hepatoprotective role through GPR109A-dependent pathway. Specifically, β-OHB supplementation (i.p. 3 mmol/kg) induced anti-inflammatory IL-10 transcripts and promoted the switch of mouse intrahepatic macrophages towards an anti-inflammatory M2 phenotype (53). This effect was mediated by the activation of protein kinase A (PKA), which reduces mitochondrial membrane potential and was no longer evident in GPR109A-knockout mice (63). GPR109A-mediated effects of β-OHB in modulating macrophage polarization (shown in Figure 2) support a key role of GPR109A signalling as anti-inflammatory regulator of the low-grade inflammation associated with insulin resistance and obesity (64).

β-hydroxybutyrate might modulate cell metabolism by engaging GPR41

Some evidence (Table 1) points to β-OHB as a novel ligand also for GPR41, a GPCR expressed in human adipocytes (65), sympathetic neurons (54) colon epithelial, endothelial (66) and mononuclear cells, and classically activated by short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate (67). Studies on knockout mice implicate GPR41 in chronic inflammatory disorders such as obesity, colitis, asthma and arthritis, although its protective or causative role is inconsistent among studies (68). Propionate potently activated sympathetic nervous system (SNS) and β-OHB - through unclear molecular mechanisms - antagonized SCFA-GPR41 signaling thereby suppressing SNS activity (55), which is known to be finely regulated for the balance of energy intake, dietary excess and starvation. This β-OHB inhibitory effect on SNS was demonstrated both in cell culture stimulated with β-OHB 10-100 mM and in streptozotocin-induced diabetic mice, in which β-OHB concentration reached 2.6 mM (55). Although other studies consider β-OHB a GPR41 agonist, rather than antagonist (54), it is established that β-OHB can control energy balance by directly regulating GPR41-mediated sympathetic activation (55). Further studies are necessary to confirm these findings and to unravel the precise molecular mechanism underlying the involvement of GPR41 in the modulation of cell metabolism.

Acetoacetate is an endogenous ligand of GPR43

GPR43 is a SCFA receptor which reduces cAMP levels, activates the ERK1/2 pathway, and increases Ca²⁺ concentrations (69). Although highly expressed in adipose tissues, it is also involved
in the modulation of inflammation and body metabolism through gut microbiota (70, 71).

Recent evidence reported that the KB acetoacetate functions as an endogenous activator of GPR43 with binding affinity comparable to that of SCFA (i.e. propionate and acetate) under ketogenic conditions (Table 1). As already stated, during fasting KB plasma concentrations were increased (>0.5 mM) and SCFA levels were highly decreased (from 0.5 to 0.1 mM), suggesting that the primary ligand for GPR43 in plasma switches from SCFAs to KB under fasting conditions.

Under ketogenic conditions acetoacetate increased plasma lipid utilization by controlling the activation of lipoprotein lipase (LPL) via adipose GPR43 (56). Furthermore, plasma levels of glucose and triglycerides were significantly reduced, and cholesterol levels increased, in wild-type compared to Gpr43−/− mice. Similarly, the decrease in body weight was significantly blunted in the Gpr43−/− mice compared with the wild-type mice during fasting. Thus, the acetoacetate-GPR43 axis plays a key role on metabolic homeostasis by controlling body weight and lipid levels.

Effects of KDs in endocrinological and metabolic disorders

The following paragraphs will discuss the results of clinical trials on the effects of KD in different metabolic and endocrinological disorders [obesity, diabetes, non-alcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome (PCOS)]. The rationale for the use of KDs is the substantial
efficacy in short-term weight loss; however, it is still unclear whether KDs may have additional benefits vs isocaloric non-ketogenic diets. In this context we will explore the hypothesis that KB, by binding to GPCR family receptors, may mediate some of these additional beneficial effects (i.e. lipid metabolism and anti-inflammatory actions). To discriminate the effects of KB per se, independently of weight loss, only studies comparing ketogenic vs isocaloric non-ketogenic diets have been herein considered, unless otherwise specified. Short-term tolerability and safety of KDs are reported in Tables 2 and 3.

We searched in Medline (PubMed) using the terms “clinical trials” in adults using the query “ketogenic diet” OR “very low carbohydrate ketogenic diet” AND “obesity”, “diabetes”, “NAFLD”, “PCOS”.

**Effects of ketogenic diets in obese subjects**

Obesity is recognized as one of the major public health hazards worldwide as it is associated with cardiometabolic and cerebrovascular diseases leading to reduced life quality and increased mortality (85). Over the past decades, there has been a rising prevalence of obesity and its prevention and treatment are mainly based on lifestyle changes, including physical activity and healthy eating habits (86).

Several studies provided robust evidence of the beneficial effect of KDs in reducing body weight in obesity. Importantly, KD-induced weight loss is generally higher than that achieved with an isocaloric non-ketogenic control diet (Table 2), as shown in several populations including hyperinsulinemic (48) overweight females (75), overweight/obese subjects (34, 72–74, 76, 77) and in morbidly obese subjects candidate to bariatric surgery (79). In addition, weight reduction following a KD is demonstrated to be accompanied by favourable changes in body composition with a higher decrease in waist circumference (48, 75, 76) and fat mass loss (72, 74), also in subjects who underwent gastric balloon procedure (80), vs control diets.

Results on weight management with KDs are generally obtained in animal models (87–90). Mice maintained on a KD exhibited higher weight reduction compared to chow-fed animals both at 6 and 12 weeks. Nevertheless, a few studies in obese mice (ob/ob) reported no differences in body weight loss between KD- and chow-fed animals (91, 92).

Favourable data of KD on metabolism have been confirmed also in human studies. A 12-week low-carbohydrate KD intervention led to a more marked improvement in glucose (48, 74, 78) and insulin (48, 49) levels compared to an isocaloric control diet in overweight/obese females (48). The amelioration in metabolic profile associated to a KD in obese subjects, has likely to be ascribed to the very low carbohydrate intake and the consequent decrease in plasma glucose/insulin levels.

KD effects on lipid profile were also reported in human studies (74, 75). A very recent systematic review of trials comparing KDs vs balanced diets in obese subjects reported no statistically significant differences in total, high-density lipoprotein (HDL) and LDL-cholesterol or triglycerides (95).

These findings may be reconciled taking into consideration the high (saturated) fat intake of these diets which might blunt/abolish the above-mentioned beneficial effects on lipid profile.

Another major point is the possible GPCR- mediated anti-inflammatory effect in course of KD.

A recent study conducted in obese individuals randomised to a 8-week VLCKD vs standard diet (both associated to an exercise program) showed a correlation between circulating β-OHB levels and the reduction of visceral fat and inflammatory markers (74) which define the adiposity state, pointing to a direct role of ketones in the amelioration of metaflammation (72). These effects should be ascribed to the activation of the β-OHB-GPR109A axis which triggers an anti-inflammatory macrophage phenotype in several animal models (50, 52, 53), ultimately reducing cardiovascular risk.

Thus, KDs might be beneficial in blunting chronic low-grade inflammation which plays a pivotal role in the pathogenesis of cardiometabolic disorders, such as obesity. Nevertheless, future studies are warranted to better explore the impact of this anti-
| Reference | Sample description | Duration | Intervention | Ketone test (concentration in KD group) | Beneficial effects of the KD vs control diet | Side effects of the KD |
|-----------|-------------------|----------|--------------|----------------------------------------|---------------------------------------------|------------------------|
| Sánchez E 2021 (72) | n=30 patients with moderate obesity | 6 months | VLCKD vs hypocaloric Mediterranean Diet | Not tested | ↓BMI | Gastrointestinal disorders (n=3) - non-fatal episode of heart failure (n=1) |
| Falkenhain K 2021 (73) | n=155 overweight/obese subjects | 12 weeks | Mediterranean ketogenic diet vs calorie-restricted, low-fat diet | Breath acetone | ↑Glucose ↓Insulin ↓HOMA-IR ↓TG ↓HDL-C ↓BMI ↓waist circ. ↓hip circ. | No adverse events reported |
| Michalczyk MM 2020 (48) | n=100 hyperinsulinemic overweight/obese females | 12 weeks | LCKD vs isocaloric control diet | β-OHB= 3.46±0.06 mM | ↓Glucose ↓fat mass ↓muscle mass ↔lipids ↓C-reactive protein ↔lean muscle mass | No adverse events reported |
| Perissiou M 2020 (74) | n=64 obese subjects | 8 weeks | LC vs standard dietary advice (both + exercise program) | Ketosis defined as β-OHB >0.3mM | ↓body fat ↓visceral adipose tissue ↓fat mass ↓muscle mass ↔lipids ↓C-reactive protein | ↓fatigue ↓constipation ↓diarrhea ↓headache |
| Sun S 2019 (75) | n=58 overweight females | 4 weeks | LC vs control diet | Urinary keto-stick | ↓BMI ↓waist circ. ↔fasting glucose ↔lipids ↓energy expenditure ↓insulin ↓C-peptide ↑FFA ↑TG ↓leptin | No adverse events reported |
| Hall KD 2016 (49) | n=17 overweight/obese males | 4 weeks of control diet followed by 4 weeks of intervention diet | LCKD vs isocaloric control diet | Plasma acetoacetate=0.78±0.07 mM β-OHB=0.76±0.07 mM | ↓energy expenditure ↑HDL-C ↑BMI ↓waist circ. ↓hip circ. ↓leptin | No adverse events reported |
| Merra G 2016 (76) | n=25 overweight/obese subjects | 3 weeks | VLCKD vs VLCD | Urinary keto-stick | ↓BMI ↓waist circ. ↔lean bodymass | No adverse events reported |
| Lobley GE 2014 (33) | n=12 obese males | 4 weeks per treatment | Cross-over LC vs MCD | Plasma acetoacetate=0.40 mMβ-OHB=0.66 mM | ↓hunger score ↔brain glucose uptake | No adverse events reported |
| Johnston AM 2008 (34) | n=17 obese males | 4 weeks per treatment | Cross-over high-protein, LCKD vs high-protein, MCD | Plasma β-OHB= 1.52 mM | ↓hunger ↓Ad libitum energy intake ↑weight loss ↑fat mass Positive correlation between ketones and perceived exertion | No adverse events reported |
| White AM 2007 (47) | n=19 overweight/obese subjects | 2 weeks | LCKD vs non-ketogenic LC | Plasma β-OHB= 0.72 ±0.18 mM | ↑weight loss ↔fat mass Positive correlation between ketones and perceived exertion | ↑fatigue ↑total mood disturbance |
| Choi HR 2018 (32) | n=46 obese subjects | 2 weeks | ketogenic nutrition drink vs isocaloric balanced nutrition drink | Urinaryketo-stick | ↔weight loss ↔fat mass ↑HDL chol. | ↑nausea ↑constipation |
| Yancy WS Jr 2004 (77) | n=120 overweight, hyperlipidemic subjects | 24 weeks | LCKD+slow fat diet | Urinary Ketones (semi-quantitative) | ↑weight loss ↓TG ↑LDL chol. ↑total mood disturbance | ↑headache ↑malaise ↑constipation ↑muscle cramps ↓diarrhea |
inflammatory mechanism in mediating the beneficial effects of KDs in obesity. Clinical trials on the effects of KDs in subjects with overweight/obesity are reported in Table 2, including adverse events.

**Effects of ketogenic diets in individuals with type 2 diabetes**

Type 2 diabetes mellitus (T2D) is a major public health global emergency (96). The dietary approach, combined with physical exercise, represents the first-line treatment in T2D. KDs have been taken into consideration, also in recent guidelines (97), among the strategies to adopt in order to obtain weight reduction, ameliorate glucose control and limit the need for anti-hyperglycemic medications in T2D (98).

In KD-fed diabetic rodents, KD strongly reduced blood glucose levels (99–103), improving glucose tolerance (102, 104) and insulin sensitivity (100, 102) compared to those fed with a control diet, even at weight loss equipoise (99, 104).

**TABLE 2 Continued**

| Reference       | Sample description                  | Duration | Intervention                          | Ketone test (concentration in KD group) | Beneficial effects of the KD vs control diet | Side effects of the KD |
|-----------------|-------------------------------------|----------|---------------------------------------|-----------------------------------------|--------------------------------------------|------------------------|
| Vazquez JA 1994 (78) | n=16 severely obese females         | 28 days  | ketogenic vs non-ketogenic VLCD       | Plasma β-OHB= 3.1 ±0.5 mM               | ↓ plasma glucose                           | ↑ weakness ↑ rash      |
| Albanese A 2019 (79) | n=178 obese subjects (candidate to bariatric surgery) | 3 weeks  | VLCKD vs VLCD                         | Not tested                              | ↑ weight loss ↓ post-operative hospital stay | No adverse events reported |
| Schiavo L 2021 (80) | n=48 obese subjects undergoing gastric balloon procedure | 4 months | Low-calorie ketogenic diet vs low-calorie diet | Ketonemia=0.18±0.2 mM                   | ↓ decrease in fat-free mass and resting metabolic rate ↑ fat mass decrease | No adverse events reported |

LCKD, low carbohydrate ketogenic diet; VLCKD, very low carbohydrate ketogenic diet; VLCD, very low calorie diet; KD, ketogenic diet; MCD, moderate carbohydrate diet; LC, low carbohydrates; BMI, body mass index; β-OHB, 3-hydroxy butyrate; TG, triglycerides.

↓, decrease; ↑, increase; ↔, no changes.

**TABLE 3 Summary of trials evaluating KD effects vs comparative diet in subjects with type 2 diabetes.**

| Reference       | Sample description                  | Duration | Intervention                          | Ketone test (concentration in KD group) | Beneficial effects | Side effects of the KD |
|-----------------|-------------------------------------|----------|---------------------------------------|-----------------------------------------|--------------------|------------------------|
| Hussain TA 2012 (81) | n=363 with T2D= 102 Age= 37.2±0.4 yr BMI= 37.3±0.3 kg/m² HbA1c= 7.9±0.1 % | 12 months | VLCKD vs low-calorie diet             | No measure                                      | ↓ HbA1c ↑ Triglycerides ↓ Total chol. ↓ LDL chol. ↑ HDL chol. | No adverse events reported |
| Goday A 2016 (82) | N=89 Age=54.5±8.4 yr BMI=33.1±1.6 kg/m² HbA1c=6.9±1.1 %² | 4 months  | Very low-calorie ketogenic diet vs low-calorie diet | Blood β-OHB(1.15 ±0.96mM)               | ↑ Triglycerides ↑ HbA1c ↑ HOMA-IR ↓ body weight ↑ Waist circumference | ↑ asthenia ↑ headache ↑ nausea ↑ vomiting ↑ constipation ↑ orthostatic hypotension |
| Saslow LR 2017 (83) | N=34 BMI=35.9±3.3 kg/m² | 12 months  | VLCKD vs MCCR                         | Blood β-OHB(values between 0.5-3.0mM)   | ↑ HbA1c body weight Diabetes medications | No adverse events reported |
| Myette Côté E 2018 (84) | N=16 Age=84±8 yr BMI=34±8 kg/m² HbA1c=7±1 % | 4 days    | VLCKD vs low-fat low-glycemic index   | No measure                                  | ↔ weight loss ↓ Mean glucose ↓ Fasting glucose | No adverse events reported |

BMI, body mass index; T2D, type 2 diabetes; β-OHB, β-hydroxybutyrate; VLCKD, very low carbohydrate ketogenic diet; HOMA-IR, Homeostasis Model Assessment for Insulin Resistance; MCCR, moderate-carbohydrate calorie-restricted.

↓, decrease; ↑, increase; ↔, no changes.
Accordingly, several studies demonstrated KD-associated beneficial effects on weight loss, lipid and glucose parameters, and insulin sensitivity in individuals with T2D (28, 81–84).

Subjects with T2D randomized to a very low-calorie KD for 4 months showed a significant reduction in weight, waist circumference, HbA1c and homeostatic model assessment for insulin resistance (HOMA-IR) compared to those allocated to a standard low-calorie diet (82). Similarly, T2D subjects following a VLCKD showed a decrease in HbA1c levels (81, 83) and an amelioration in lipid profile (81) compared to those on a control diet. A KD-induced decrease in glucose parameters was also confirmed in a short-term (4 days) clinical study (84). Of note, VLCKD consumption was also associated to a reduction in diabetes medication use compared to non-ketogenic control diet (83).

Mechanistically, lipid profile amelioration in T2D by VLCKD could be ascribed to the above-described actions of acetoacetate via GPR43 (56) and of β-OHB via GPR109A on lipolysis (46, 51) and to the insulin resistance amelioration.

Conversely, the improvement in glucose profile associated to the consumption of a KD in T2D is unlikely to be mediated by GPCR activation, but rather by the limited carbohydrate intake. Results from controlled clinical trials on the effects of KD in subjects with T2D are summarized in Table 3.

Despite these limited but encouraging results, it should be taken into consideration that carbohydrate restriction associated to KDs may increase the risk of hypoglycemia in these patients, especially in those treated with insulin and/or insulin secretagogues. Thus, KDs should be initiated under strict medical supervision, particularly in course of diuretic therapy, in order to avoid hypoglycemia and dehydration (105, 106). Importantly, KDs should not be prescribed to patients treated with sodium-glucose cotransporter (SGLT)-2 inhibitors for their significantly higher risk of developing euglycemic diabetic ketoacidosis (28, 107). Indeed, this drug class enhances the production of KB in the liver, by increasing glucagon levels and reducing the insulin:glucagon ratio per se (108–110).

Effects of ketogenic diets in subjects with type 1 diabetes

Clinical trials investigating KD effects in individuals with type 1 diabetes (T1D) are very limited. The randomization to a VLCKD in a cross-over study reduced glucose variability compared to an isocaloric high-carbohydrate diet (111). Nevertheless, in an uncontrolled study the consumption of a VLCKD was associated to a high risk of dyslipidaemia and to a high frequency of hypoglycaemic episodes in T1D subjects (112). Interestingly, a case report showed that a healthy young woman, in course of a KD for weight reduction, developed diabetic ketoacidosis which was considered the “precipitating factor” leading to T1D diagnosis (113).

Thus, a KD might be appropriate for selected T1D patients, but only following a careful evaluation of the burden of risks (dyslipidemia, diabetic ketoacidosis and hypoglycemia) and benefits (weight loss and better glycemic control) (114). Nonetheless, the latest Standards of Medical Care by American Diabetes Association do not recommend KDs in the medical nutrition therapy for T1D (115).

Effects of ketogenic diets in individuals with NAFLD

NAFLD is a metabolic liver disease strongly associated with obesity and T2D; its prevalence is increasing - it affects a quarter of global population- along with that of other metabolic disorders. NAFLD is the commonest cause of chronic liver disease and it is defined as an increase in liver fat content, in the absence of secondary cause of steatosis (116). In fact, the clinical onset of the disease is a much more complex process, closely related to insulin resistance and to the limited expandability and dysfunctionality of adipose tissue (117).

In obese mice, a 3-week VLCKD regimen increased pro-inflammatory M1/M2 macrophage ratio in adipose tissue without ameliorating NAFLD, in contrast to the low-fat control diet (118). In line, long-term administration of a KD in mice induced systemic glucose intolerance, hepatic ER stress, steatosis, cellular injury and macrophage accumulation (90). Though, data from the literature are discordant as a very recent paper demonstrated that KD prevented steatosis and insulin resistance by reducing lipogenesis, diacylglycerol accumulation and protein kinase C activity in rat liver (119).

In humans, a very recent randomized 6-week intervention trial showed that the consumption of a KD or an isocaloric low-fat diet similarly and safely reduced liver fat in individuals with NAFLD (120). Nevertheless, randomized trials on subjects with NAFLD are deficient, and the efficacy of KD in NAFLD is still a matter of debate.

KDs may display a dual effect in NAFLD treatment. If on the one hand KD-mediated reduction in insulinemia and lipogenesis and increase in FFA oxidation (121) are beneficial; on the other, the high fat content of the diet might worsen liver fat accumulation.

Therefore, long-term randomized clinical trials are needed to assess safety and efficacy of KDs in NAFLD (122).

Effects of ketogenic diets in women with polycystic ovary syndrome

PCOS is an endocrine disorder characterized by anovulation, polycystic ovaries and hirsutism. PCOS is often associated to insulin resistance, dyslipidaemia, NAFLD, obesity, and ultimately...
to an augmented risk for the development of cardiometabolic diseases. To the best of our knowledge, no studies to date have compared the effects of a KD versus a non-ketogenic control diet in women with PCOS. Nevertheless, some pilot short-term uncontrolled studies in overweight (123) and obese (124, 125) women with PCOS showed beneficial effects of KDs in reducing body weight, fat mass (123, 124), visceral adipose tissue (123) and cholesterol levels, accompanied by an improvement in insulin sensitivity (reduced HOMA-IR) (123, 124) and to a reduction in cholesterol levels, accompanied by an improvement in insulin ratio and testosterone levels (123). In a very recent study conducted in 18 obese women with PCOS and liver dysfunction the intake of a KD for 12 weeks was more effective compared to a conventional pharmacological treatment (polyene phosphatidylcholine) in reducing fasting glucose, body weight and liver enzymes; both interventions equally decreased plasma estradiol and progesterone levels (126). In conclusion, comparative studies are needed to ascertain whether KDs may display additional endocrinological and metabolic benefits in PCOS, independently of weight loss.

**Discussion**

Nutritional ketosis induced through a ketogenic diet leads to higher, but controlled, plasma ketone concentrations (>0.5–1.0 mM). Most human studies provide evidence of a higher effect in short-term weight loss of the KDs compared to isocaloric balanced diets in T2D and obese/overweight subjects, nevertheless controversies remain about the use of KDs in other metabolic disease such as T1D and NAFLD. Scarce evidence exists regarding the effects of KDs in PCOS.

The important weight loss effect with KDs compared to standard diets is largely attributable to higher plasma ketones (31, 127); however, the exact threshold of ketosis needed to control appetite, as well as the exact mechanisms underlying this effect have yet to be established.

KD might also display additional cardiometabolic benefits, beyond (and in addition to) weight loss, which may rely on different mechanisms. The very limited carbohydrate assumption mainly accounts for the improvement in glucose levels and insulin resistance, often reported in subjects with obesity/diabetes.

Recent evidence supports a different mechanism for KD effects on the amelioration in lipid profile (in particular triglycerides) and inflammation which might be of particular relevance in insulin resistance-related disorders. Ketones can bind specific GPCRs - i.e. GPR109A (50), GPR41 (55) and GPR43 (56) - through which they are able to directly modulate lipid metabolism and inflammation. The activation of acetoacetate-GPR43 axis promotes lipid utilization by plasma LPL activation (56), whilst that of GPR109A by β-OHB decreased adipocytic lipase activity and consequent hepatic triglyceride synthesis (46, 51). In addition, the activation of GPR41 by β-OHB may probably negatively regulate energy intake and metabolism through the suppression of sympathetic activation (55). Comparably, GPR109A-mediated inhibition of NLRP3 inflammasome by β-OHB presumably accounts for the anti-inflammatory effects associated to a KD regimen, leading to an anti-atherogenic polarization of macrophages in M2 phenotype (1, 45, 50, 52).

However, despite a strong preclinical and animal evidence, (45, 50, 52) points to a role of ketones in the reduction of inflammation - which is a common trait of metabolic diseases - a robust clinical confirmation is still lacking. Mechanistic human studies are warranted to ascertain whether GPCR signalling activation by ketones might be of clinical relevance in favourably affecting lipid and inflammatory profiles, independently or in addition to the important weight reduction.

Human intervention studies with KDs are fraught with important limitations since high-quality and long-term evidence is currently scant.

Most interventions span over a period of a few weeks and KD adherence is limited by the very low carbohydrate content (<50g/day) (16). In addition, many studies report only partial data on calories/macronutrients composition of the diets and on the achieved plasma ketone levels, which may account for result heterogeneity among different studies. Ultimately, data on long-term beneficial effects and safety of KD on metabolic/endocrinological disorders are still needed.

In conclusion, although KDs hold a strong potential in the treatment of endocrinological and metabolic disorders due to a broader spectrum of short-term beneficial therapeutic effects in reducing weight and appetite, in ameliorating lipid and glucose profile and the inflammatory milieu, definitive conclusions are difficult to be drawn.

**Author contributions**

VS, GC and ADC concepted and designed the review and wrote the manuscript. NTI, GF, GM, MM and VP contributed to the review and interpretation of the literature and drafted the manuscript. ADC critically revised the manuscript. All authors contributed to the article and approved the submitted version.

**Funding**

This paper has been supported by "FIL funds for research" from University of Parma to ADC.

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Laffel L. Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab Res Rev (1999) 15(6):412-26. doi: 10.1002/(sici)1520-7560(199911)15:6<412::aid-dmr65>3.0.co;2-v
2. Puchalska P, Crawford PA. Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics. Cell Metab (2017) 25(2):262–84. doi: 10.1016/j.cmet.2016.12.022
3. Kohlmeier M. Nutrient metabolism. London: Academic Press (2003).
4. Cahill GF. Veech RL. Ketocidosis? good medicine? Trans Am Clin Climatol Assoc (2003) 114:149–61
5. Dhillon KK, Gupta S. Biochemistry, ketogenesis. In: StatPearls. Treasure Island (FL: StatPearls Publishing (2021). Available at: https://www.ncbi.nlm.nih.gov/books/NBK493179/
6. Karpe F, Dickmann JR, Frayn KN. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes (2011) 60(10):2441–9. doi: 10.2337/db11-0425
7. Pinckaers PJ. Churchward-Venne TA, Bailey D, van Loon LJ. Ketone bodies and exercise performance: The next magic bullet or merely hype? Sports Med (2017) 47(3):383–91. doi: 10.1007/s40279-016-0577-y
8. Barnett CR, Barnett YA. Ketone bodies. In: Caballero B, editor. Encyclopedia of food sciences and nutrition, 2. (San Diego, California, USA: Academic Press) (2003). pp. 42–5.
9. Caprio M, Infante M, Moriconi E, Armani A, Fabbrì A, Mantovani G, et al. Cardiovascular endocrinology club of the Italian society of endocrinology: very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: a systematic review and consensus statement from the Italian society of endocrinology (SIE). J Endocrinol Invest. (2019) 42(11):1365–86. doi: 10.1007/s40618-019-01061-2
10. Sheikh-Ali M, Karon BS, Basu A, Kidva YC, Muller LA, Xu J, et al. Can serum beta-hydroxybutyrate be used to diagnose diabetic ketocidosis? Diabetes Care (2008) 31(4):643–7. doi: 10.2373/diabetes.07-1683
11. Ford W, SW Holst, Vos C, McNaughton CD. Diabetes in the emergency department and hospital: Acute care of diabetes patients. Curr Emerg Hosp Med Top (2013) (11):1–9. doi: 10.1016/j.chmt.2013.11.007
12. Widerøe RM. The effects of ketonemia on the course of epilepsy. Mayo Clin Proc (1921) 2397–8.
13. Augustin K, Khubabu A, Williams S, Eaton S, Orford M, Cross JH, et al. Mechanisms of action for the medium-chain triglyceride ketogenic diet in neurological and metabolic disorders. Lancet Neurol (2011) 17(1):84–93. doi: 10.1016/S1474-4422(13)70408-8
14. Klemm RJ, Champ CE, Otto C, Kammerer U. Anti-tumor effects of medium-chain triglyceride ketogenic diet in endocrine disorders: Current perspectives. J Postgrad Med (2017) 63(4):242–51. doi: 10.1003/jpgm.16_17
15. Spigoni et al. 10.3389/fendo.2022.972890
16. Hassan AM, Keene DL, Whiting SE, Jacob PJ, Champagne JR, Humphreys P. Ketogenic diet in the treatment of refractory epilepsy in childhood. Pediatr Neurol (1999) 21(2):548–52. doi: 10.1016/s0888-8750(99)00045-4
17. Couppola G, Veggio P, Causani R, Bertoli S, Cardinali S, Dionisi-Vici C, et al. The ketogenic diet in children, adolescents and young adults with refractory epilepsy: an Italian multicentric experience. Epilepsia (2002) 43(3):221–7. doi: 10.1016/s0013-5866(02)01152-3
18. Huttonelcher PR, Wilbourn AJ, Signore [M. Medium-chain triglycerides as a therapy for intractable childhood epilepsy. Neurology (1971) 21(11):1097–103. doi: 10.1212/wnl.21.11.1097
19. Zupe-Kania BA, Spellman E. An overview of the ketogenic diet for pediatric epilepsy. Nutr Clin Pract (2008) 23(6):589–96. doi: 10.1177/0884533608326138
20. Chang P, Terbach N, Plant N, Chen PE, Walker MC, Williams RS. Seizure control by ketogenic diet-associated medium fatty acids. Neuropharmacology (2013) 69:105–14. doi: 10.1016/j.neuropharm.2012.11.004
21. Liu YM. Medium-chain triglyceride (MCT) ketogenic therapy. Epilepsia (2008) 49 Suppl 3:33–6. doi: 10.1111/j.1528-1167.2008.01830.x
22. Henderson ST, Vogel JL, Barr L, Gavin F, Jones J, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate alzheimer’s disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond.) (2009) 6:31. doi: 10.1186/1743-7707-6:31
23. Gibson AA, Seimon BV, Lee CM, Ayre J, Franklin J, Markovic TP, et al. Do ketogenic diets really suppress appetite? a systematic review and meta-analysis. Obes Rev (2015) 16(1):64–76. doi: 10.1111/obr.12230
24. Gupta L, Khandelwal D, Kalra S, Gupta P, Dutta D, Aggarwal S. Ketogenic diet in endocrine disorders: Current perspectives. J Postgrad Med (2017) 63(4):242–51. doi: 10.1003/jpgm.16_17
25. Trezizhan N, Doets EL, Vonk Noordegraaf-Schouten M. Extensive literature search and review as preparatory work for the evaluation of the essential composition of total diet replacement products for weight control. EFSA Supporting Publications. (2015) 12:9506. doi: 10.2903/esfa.2015.EN-590
26. Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, et al. Ketosis and appetite-mediating nutrients and hormones after weight loss. Erz J Clin Nutr (2013) 67(7):579–64. doi: 10.1038/ejcn.2013.90
27. Deemer SE, Praisland EP, Martins C. Impact of ketosis on appetite regulation–a review. Nutrients (2020) 77:1–11. doi: 10.3390/nu12020218
28. Choi HR, Kim J, Lim H, Park YK. Two-week exclusive supplementation of modified ketogenic nutrition drink reserves lean body mass and improves blood lipid profile in obese adults: A randomized clinical trial. Nutrients (2018) 10(12):1895. doi: 10.3390/nu10121895
29. Lobley GE, Johnstone AM, Fyfe C, Horgan GW, Holtopl G, Bremner DM, et al. Glucose uptake by the brain on chronic high-protein weight-loss diets with either moderate or low amounts of carbohydrate. Br J Nutr (2014) 111(4):586–97. doi: 10.1017/s0007114513002980
30. Johnstone AM, Horgan GW, Murison SD, Bremner DM, Lobley GE. Effects of a high-protein ketogenic diet on hunger, appetite, and weight loss in obese men feeding ad libitum. Am J Clin Nutr (2008) 87(1):44–55. doi: 10.1093/ajcn/87.1.44
31. Masood W, Annamaraju P, Uppaluri KR. Ketogenic diet. In: StatPearls. Treasure Island (FL: StatPearls Publishing (2021).
32. Batch JT, Lamsal SP, Adkins M, Sultán, S, Ramirez MN. Advantages and Disadvantages of the Ketogenic Diet: A Review Article. Currrevs (2020) 12(3):e9639. doi: 10.7759/currevs.9639
33. Ang D, Zhou Q, Lahrosa V, Qin S, Darbalai S, Wu Y, et al. G Protein-coupled receptors: structure- and function-based drug discovery. Signal Transduct Target Ther (2021) 6(1):7. doi: 10.1038/s41392-020-00435-w
34. Stevens RC, Cherezov V, Kartovich V, Abagyan R, Kuhn P, Rosen H, et al. The GPCR network: a large-scale collaboration to determine human GPCR structure and function. Nat Rev Drug Discovery (2013) 12(1):25–34. doi: 10.1038/nrd3859
39. Priyadarshini M, Villa SR, Fuller M, Wicksted B, Mackay CR, Alquier T, et al. FFAR3 regulates insulin secretion. Mol Endocrinol (2015) 29(7):1055–66. doi: 10.1210/me.2015-1007.

40. Liu C, Wu J, Zhu J, Kuri C, Yu J, Shelton J, et al. Lactate inhibits lipolysis in fat cells through activation of an orphan G-protein-coupled receptor, GPR83. J Biol Chem (2009) 284(5):2813–22. doi: 10.1074/jbc.M804922000.

41. Hurtel A-S, Traudel M, Rudenko O, Horath SA, Schwartz TW, GPCR-mediated signaling of metabolites. Cell Metab (2017) 25(4):774–96. doi: 10.1016/j.cmet.2017.03.008.

42. Senior B, Lorigan L. Direct regulatory effect of ketones on lipolysis and on glucose concentrations in man. Nature (1966) 215(5113):83–4. doi: 10.1038/215083a0.

43. Cahill GF Jr. Starvation in man. Adv Sci (Weinh). (2010) 4:1829. doi:10.1038/nature08530.

44. Leitinger N, Schulman IG. Phenotypic polarization of macrophages in atherosclerosis. Translational approaches to develop targeted therapies. Hepatology (2016) 64(4):1343–55. doi: 10.1002/hep.28530.

45. Rahman M, Muhammad S, Khan MA, Hoek A, et al. Regulation of adipogenic production in human adipose tissue by propionic acid. Eur J Clin Invest. (2010) 40(5):401–7. doi: 10.1111/j.1365-2362.2010.02278.x.

46. Le, Cao Z, Lai X, Wang W, Guz Z, Yan L, et al. Nicacin fine-tunes energy homeostasis through canonical GPR109A signaling. FASEB J (2019) 33(4):4765–.

47. Mandrekar P, Bataller R, Tsukamoto H, Gao B. Alcoholic hepatitis: Translational approaches to develop targeted therapies. Hepatology (2016) 64(4):1343–55. doi: 10.1002/hep.28530.

48. Spigoni et al. 10.3389/fendo.2022.972890.
Signal Transduct Target Ther (2021) 6(4):e18604. doi: 10.1038/s41392-021-00831-w

Poplawski MM, Mastaitis JW, Joda F, Grosjean F, Zheng F, Mobbs CV. Reversal of diabetic nephropathy by a ketogenic diet. PLoS One (2011) 6(4):e18604. doi: 10.1371/journal.pone.0018604

Yang Z, Mi J, Wang Y, Yue L, Liu J, Fan M, et al. Effects of low-carbohydrate diet and ketogenic diet on glucose and lipid metabolism in type 2 diabetic mice. Nutrition (2021) 89:11230. doi: 10.1016/j.nut.2021.11230

Gao Y, Zhang C, Shang FF, Luo M, You Y, Zhao Q, et al. Ketogenic diet ameliorates cardiac dysfunction via balancing mitochondrial dynamics and inhibiting apoptosis in type 2 diabetic mice. Aging (2020) 12(11):229–40. doi: 10.14336/AD.2019.0510

Zhang X, Qin J, Zhan Y, Shi J, Lan R, Gan Y, et al. Long-term ketogenic diet contributes to glycemic control but promotes lipid accumulation and hepatic steatosis in type 2 diabetic mice. Nutr (2016) 36(4):349–58. doi: 10.1016/j.nut.2015.12.002

Yancy WSJr, Foy M, Chalecki AM, Vernon MC, Westman EC. A low-carbohydrate, ketogenic diet to treat type 2 diabetes. Nutr (2005) 202(5):725–9. doi: 10.1023/B:ADIO.0000016863.84840.ff

Kalra S, Jain A, Ved J, Unnikrishnan AG. Sodium-glucose cotransporter 2 inhibition and health benefits: The robin hood effect. Indian J Endocrinol Metab (2015) 19(4):524–8. doi: 10.4103/2230-8210.157839

Ferrannini E, Muscilli E, Fracassa S, Baldi S, Mari A, Heise T, et al. Metabolic response to sodium glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest (2014) 124(2):499–508. doi: 10.1172/JCI72227

Kalra S, Sahay R, Gupta Y. Sodium glucose cotransporter 2 (SGLT2) inhibition and ketogenesis. Indian J Endocrinol Metab (2015) 19(4):524–8. doi: 10.4103/2230-8210.157839

Ranjan A, Schmidt S, Damm-Frydenborg C, Holst J, Madhusodan S, Norgaard K. Short-term effects of a low-carbohydrate diet on glycemic variables and cardiovascular risk markers in patients with type 1 diabetes: A randomized open-label crossover trial. Diabetes Obes Metab (2017) 19(10):1479–84. doi: 10.1111/dob.12953

Leow ZZK, Guellf EJ, Davis EA, Jones TW, Fournier PA. The glycaemic benefits of a very-low-carbohydrate ketogenic diet in adult with type 1 diabetes mellitus may be opposed by increased hypoglycaemia risk and dyslipidaemia. Diabetes Med (2018) doi: 10.1111/dme.13663

Chomczynski S, Sothernre J, Titrattanakul P, Pongchayakul C. Ketogenic diet-induced diabetic ketoacidosis in a young adult with unrecognized type 1 diabetes. Case Rep Endocrinol (2021) 2021:6620832. doi: 10.1155/2021/6620832

Buehlter LA, Noe D, Knapp S, Isaacs D, Pantalone KM. Ketogenic diets in the management of type 1 diabetes. Safe or safety concern? Cleve Clin J Med (2021) 88(10):547–55. doi: 10.3949/ccj.88a2021

American Diabetes Association. 5. facilitating behavior change and well-being to improve health outcomes: Standards of medical care in diabetes–2021. Diabetes Care (2021) 44(Supplement_1):S1–52. doi: 10.2337/dci21-0005

Godoy-Matos AF, Silva Junior WS, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetes Metab Syndr (2020) 12:60. doi: 10.1016/j.dsx.2020.05.070

Yamazaki T, Okawa S, Takahashi M. The effects on weight loss and gene expression in adipose tissue and hepatic very-low-carbohydrate at low-fat ketogenic diets in mice. Am J Physiol Endocrinol Metabol (2007) 292(6):E1724–9. doi: 10.1152/ajpendo.00357.2009

Badman MK, Kennedy AR, Adams AC, Pissios P, Maratos-Flier E. A very low-carbohydrate, high-fat ketogenic diet induces a unique metabolic state in mice. Am J Physiol Endocrinol Metabol (2007) 292(6):E1724–9. doi: 10.1152/ajpendo.00357.2009

Spigoni et al. 10.3389/fendo.2022.972890
122. Parra-Vargas M, Rodriguez-Echevarria R, Jimenez-Chillaron JC. Nutritional approaches for the management of nonalcoholic fatty liver disease: An evidence-based review. *Nutrients* (2020) 12(12):3860. doi:10.3390/nu12123860

123. Paoli A, Mancin L, Giacona MC, Bianco A, Caprio M. Effects of a ketogenic diet in overweight women with polycystic ovary syndrome. *J Transl Med* (2020) 18(1):104. doi:10.1186/s12967-020-02277-0

124. Canciones RI, Losavio F, Ciolli F, Valenzano A, Cibelli G, Messina G, et al. Effects of mixed of a ketogenic diet in overweight and obese women with polycystic ovary syndrome. *Int J Environ Res Public Health* (2021) 18(23):12490. doi:10.3390/ijerph182312490

125. Mavropoulos JC, Yancy WS, Hepburn J, Westman EC. The effects of a low-carbohydrate, ketogenic diet on the polycystic ovary syndrome: a pilot study. *Nutr Metab (Lond)*. (2005) 2:35. doi: 10.1186/1743-7075-2-35

126. Li J, Bai WP, Jiang B, Bai LR, Gu B, Yan SX, et al. Ketogenic diet in women with polycystic ovary syndrome and liver dysfunction who are obese: A randomized, open-label, parallel-group, controlled pilot trial. *J Obstet Gynaecol Res* (2021) 47(3):1145–52. doi: 10.1111/jog.14650

127. Sukkar SG, Muscaritoli M. A clinical perspective of low carbohydrate ketogenic diets: A narrative review. *Front Nutr* (2021) 8:642628. doi: 10.3389/fnut.2021.642628